Cosmo Pharmaceuticals Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 347

Employees

  • Stock Symbol
  • CMHC

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $68.42
  • (As of Friday Closing)

Cosmo Pharmaceuticals General Information

Description

Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7th Floor, One North Dock
  • 91/94 North Wall Quay
  • Dublin D01 H7V7
  • Ireland
+353 (01)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
SWX
Corporate Office
  • 7th Floor, One North Dock
  • 91/94 North Wall Quay
  • Dublin D01 H7V7
  • Ireland
+353 (01)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cosmo Pharmaceuticals Stock Performance

As of 13-Nov-2026, Cosmo Pharmaceuticals’s stock price is $68.42. Its current market cap is $1.18B with 17.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$68.42 $70.28 $58.74 - $166.08 $1.18B 17.2M 33.2K -$0.44

Cosmo Pharmaceuticals Financials Summary

As of 30-Jun-2026, Cosmo Pharmaceuticals has a trailing 12-month revenue of $120M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,281,593 1,985,918 999,658 924,037
Revenue 119,789 117,509 288,691 100,395
EBITDA 9,708 12,298 177,503 10,624
Net Income (7,410) (4,070) 144,175 (11,668)
Total Assets 791,872 719,615 673,013 581,490
Total Debt 4,926 5,010 2,290 2,033
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cosmo Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cosmo Pharmaceuticals‘s full profile, request access.

Request a free trial

Cosmo Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, an
Pharmaceuticals
Dublin, Ireland
347 As of 2026

Melbourne, Australia
 

Pune, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cosmo Pharmaceuticals Competitors (44)

One of Cosmo Pharmaceuticals’s 44 competitors is Clinuvel Pharmaceuticals, a Corporation company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clinuvel Pharmaceuticals Corporation Melbourne, Australia
Brinton Pharmaceuticals Private Equity-Backed Pune, India
Novartis Corporation Basel, Switzerland
Assertio Holdings Formerly VC-backed Lake Forest, IL
Lilly USA Corporation Indianapolis, IN
You’re viewing 5 of 44 competitors. Get the full list »

Cosmo Pharmaceuticals Patents

Cosmo Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2453243-A1 Method for the diagnosis and/or follow up of the evolution of a tumor Inactive 11-Nov-2010
WO-2012062831-A1 Method for the diagnosis and/or follow up of the evolution of a tumor Inactive 11-Nov-2010
US-11938141-B2 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Active 03-Aug-2007
US-12337002-B2 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Active 03-Aug-2007
US-20220280531-A1 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Active 03-Aug-2007 C07J5/0053
To view Cosmo Pharmaceuticals’s complete patent history, request access »

Cosmo Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cosmo Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cosmo Pharmaceuticals‘s full profile, request access.

Request a free trial

Cosmo Pharmaceuticals Investments & Acquisitions (8)

Cosmo Pharmaceuticals’s most recent deal was a Merger/Acquisition with Cassiopea for . The deal was made on 17-Dec-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cassiopea 17-Dec-2021 Merger/Acquisition Drug Discovery
Acacia Pharma 02-Jan-2020 PIPE Pharmaceuticals
Linkverse 01-Mar-2019 Secondary Transaction - Private IT Consulting and Outsourcing
Linkverse 01-Jan-2018 Merger/Acquisition IT Consulting and Outsourcing
Paion 27-Jun-2016 PIPE Pharmaceuticals
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Cosmo Pharmaceuticals ESG

Risk Overview

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Cosmo Pharmaceuticals’s complete esg history, request access »

Cosmo Pharmaceuticals Exits (3)

Cosmo Pharmaceuticals’s most recent exit was on 02-Jan-2020 from Acacia Pharma. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Acacia Pharma 02-Jan-2020 Completed
Paion 27-Jun-2016 Completed
AIMM Therapeutics 07-Jun-2013 Later Stage VC Completed
To view Cosmo Pharmaceuticals’s complete exits history, request access »

Cosmo Pharmaceuticals Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Cosmo Artificial Intelligence - Ai Dublin, Ireland 2015
Salix Pharmaceuticals (Dublin) Dublin, Ireland 2004

Cosmo Pharmaceuticals FAQs

  • When was Cosmo Pharmaceuticals founded?

    Cosmo Pharmaceuticals was founded in 1997.

  • Where is Cosmo Pharmaceuticals headquartered?

    Cosmo Pharmaceuticals is headquartered in Dublin, Ireland.

  • What is the size of Cosmo Pharmaceuticals?

    Cosmo Pharmaceuticals has 347 total employees.

  • What industry is Cosmo Pharmaceuticals in?

    Cosmo Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Cosmo Pharmaceuticals a private or public company?

    Cosmo Pharmaceuticals is a Public company.

  • What is Cosmo Pharmaceuticals’s stock symbol?

    The ticker symbol for Cosmo Pharmaceuticals is CMHC.

  • What is the current stock price of Cosmo Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Cosmo Pharmaceuticals is $68.42.

  • What is the current market cap of Cosmo Pharmaceuticals?

    The current market capitalization of Cosmo Pharmaceuticals is $1.18B.

  • What is Cosmo Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Cosmo Pharmaceuticals is $120M.

  • Who are Cosmo Pharmaceuticals’s competitors?

    Clinuvel Pharmaceuticals, Brinton Pharmaceuticals, Novartis, Assertio Holdings, and Lilly USA are some of the 44 competitors of Cosmo Pharmaceuticals.

  • What is Cosmo Pharmaceuticals’s annual earnings per share (EPS)?

    Cosmo Pharmaceuticals’s EPS for 12 months was -$0.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process